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Methylation
p53Long noncoding RNAs (lncRNAs) are being increasingly recognized as major players in governing fundamental
biological processes through diverse mechanisms. Maternally expressed gene 3 (MEG3) is an imprinted gene
located at 14q32 that encodes a lncRNA correlated with several human cancers. Recently, the methylation-
dependent downregulation of MEG3 has been described in liver cancers. However, its biological functional role
in liver ﬁbrosis remains unknown. In our study, MEG3 levels were remarkably decreased in CCl4-induced
mouse liver ﬁbrosis models and human ﬁbrotic livers as demonstrated by real-time quantitative PCR. Moreover,
the expression of MEG3 was downregulated in human hepatic stellate cell lines LX-2 cells in response to
transforming growth factor-β1 (TGF-β1) stimulation in dose and time-dependent manner. Enforced expression
of MEG3 in LX-2 cells inhibited TGF-β1-induced cell proliferation, while promoting cell apoptosis. In addition,
hypermethylation of MEG3 promoter was identiﬁed by methylation-speciﬁc PCR and MEG3 expression was
robustly increased by the inhibition of methylation with either 5-aza-2-deoxycytidine (5-azadC), or siRNA to
DNA methyltransferase 1 (DNMT1) in TGF-β1-induced LX-2 cells. More importantly, overexpression of MEG3
could activate p53 and mediate cytochrome c release, subsequently leading to caspase-3-dependent apoptosis
in TGF-β1-treated LX-2 cells. These ﬁndings suggested that MEG3 may play an important role in stellate cell
activation and liver ﬁbrosis progression and act as a novel potential therapeutic target for liver ﬁbrosis.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Hepatic ﬁbrosis, characterized by the excessive deposition of extracel-
lular matrix (ECM) in response to chronic hepatic injury, is themajor de-
terminant of morbidity and mortality in patients with liver disease [1,2].
Following chronic liver injury of any cause, hepatic stellate cells (HSCs)
become activated and transdifferentiate to myoﬁbroblast-like cells by
the secretion of excessive ECM proteins including α-smooth muscle
actin (α-SMA) and alpha1(1) collagen (Col1A1), by the release of pro-
inﬂammatory and pro-ﬁbrogenic factors including transforming growthternallyexpressedgene3;ECM,
te dehydrogenase; HSC, hepatic
platelet-derived growth factor;
bovine serum; PBS, phosphate
-smooth muscle actin; Col1A1,
einase-1;MMP-2,matrixmetal-
T1, DNAmethyltransferase 1; 5-
A
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551 65161001.
.cn (J. Li).factor-β1 (TGF-β1) and platelet-derived growth factor (PDGF) [3]. It is
well accepted that activation of HSCs is a pivotal event during liver
ﬁbrogenesis [4–6]. However, better ﬁguring out the mechanisms of HSC
activation is still beyond our reach because of its complexity.
Regulatory noncoding RNAs (ncRNAs), such asmicroRNAs (miRNAs),
a great variety of long noncoding RNAs (lncRNAs), play increasingly key
roles in the development of humandiseases [7–10]. LncRNA is commonly
deﬁned as a RNA molecular which is larger than 200 nucleotides (nt)
with limited or no protein-coding capacity [11,12]. A large and growing
body of literature shows that involvement of lncRNAs in liver diseases,
and in liver cancers in particular [10,13]. For example, a lncRNA, down-
regulated expression by HBx (termed lncRNA-Dreh), which could inhibit
hepatocellular carcinoma (HCC) growth and metastasis in vitro and
in vivo, act as a tumor suppressor in the development of HBV–HCC [14].
Deregulation of lncRNAMVIH (lncRNA associatedwithmicrovascular in-
vasion in HCC) was a predictor for poor recurrence-free survival (RFS) of
HCC patients after hepatectomy and the inhibition of phosphoglycerate
kinase 1 (PGK1) secretion by its associationwithMVIH contributed to ac-
tive angiogenesis both in vitro and in vivo [15]. Furthermore, LncRNA
highly up-regulated in liver cancer (HULC) was dramatically up-
regulated in HCC and the up-regulated HULC by HBx promoted
Table 1
Primers used in real-time qRT-PCR.
Gene Number gene primer (5′ → 3′)
α-SMA F: 5′-GGCTCTGGGCTCTGTAAGG-3′
R: 5′-CTCTTGCTCTGGGCTTCATC-3′
Col1A1 F: 5′-CCCGGGTTTCAGAGACAACTTC-3′
R: 5′- TCCACATGCTTTATTCCAGCAATC-3′
TIMP-1 F: 5′-AATTCCGACCTCGTCATCAG-3′
R: 5′- TGCAGTTTTCCAGCAATGAG-3′
MMP2 F: 5′-AACTACGATGATGACCGCAAG-3′
R: 5′-GACAGACGGAAGTTCTTGGTG-3′
MMP9 F: 5′-TCGAACTTTGACAGCGACAAGAA-3′
R: 5′-TCAGTGAAGCGGTACATAGGGTACA-3′
DNMT1 F: 5′-CGGTTCTTCCTCCTGGAGAATGTCA-3′
R: 5′-CACTGATAGCCCATGCGGACCA-3′
GAPDH F: 5′-ACCACAGTCCATGCCATCAC-3′
R: 5′-TCCACCACCCTGTTGCTGTA-3′
F, forward primer; R, reverse primer.
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whether lncRNA is involved in the development of nonneoplastic liver
diseases has not been elucidated so far.
Maternally expressed gene 3 (MEG3), a lncRNA, is expressed in
many normal tissues and functions as a lncRNA tumor suppressor [17,
18]. Recently, the loss of MEG3 expression has been gradually proved
to be a primary feature of human cancers, such as liver cancer [17,19],
gastric cancer [20,21], lung cancer [22], glioma [23], cervical cancer
[24], bladder cancer [25] and so on. Furthermore, promoter hyperme-
thylation or hypermethylation of the differentially methylated regions
(DMRs) has been found to contribute to the loss of MEG3 expression
in cancers [26–28]. Moreover, MEG3 could induce the accumulation of
p53 (TP53) protein, selectively regulate p53 target gene expression
leading to cell growth inhibition [29]. However, very little is known
about MEG3 expression level and its biological role in the progression
of liver ﬁbrosis.
In this study, we ﬁrstly demonstrated that MEG3 expression was
signiﬁcantly decreased in both CCl4-induced mouse liver ﬁbrosis
models and human ﬁbrotic livers. Furthermore, our results showed
the antiﬁbrotic effect of MEG3 on TGF-β1-induced LX-2 cells activation.
The effect of DNAmethylation onMEG3 expressionwas also investigat-
ed. We further veriﬁed that overexpression of MEG3 could induce the
activation of p53 and mediate cytochrome c release subsequently lead-
ing to caspase-3-dependent apoptosis in TGF-β1-treated LX-2 cells.
Taken together, our ﬁndings indicated that lncRNA MEG3 may repre-
sent a novel regulator to modulate stellate cells activation and could
serve as a potential therapeutic target against liver ﬁbrosis.
2. Materials and methods
2.1. Animals, mouse models of liver ﬁbrosis, patients
Each 6 adult (8-week-old)male C57BL/6J mice from the Experimen-
tal Animal Center of Anhui Medical University were used for CCl4 liver
injury model. The animal experimental procedures were reviewed and
approved by theUniversity Animal Care andUseCommittee. Liverﬁbro-
sis was generated by biweekly intraperitoneal dose of a 10% solution of
CCl4 in olive oil (0.02 ml/g/mouse) for the ﬁrst 4 weeks and then once a
week as previously described [30]. At weeks 4, 6 or 8, the mice were
sacriﬁced. Control mice were treated intraperitoneally with the same
volume of olive oil at the same time intervals. 24 h after the last CCl4
injection mice were sacriﬁced and liver tissues were harvested for the
further analysis. The liver tissues were used for hematoxylin and eosin
(H&E) staining and Masson staining by ﬁxation with 10% formalin.
Human liver ﬁbrotic tissue samples were obtained from patients
undergoing partial liver resection at the Department of Surgery, the
First Afﬁliated Hospital of Anhui Medical University. As a control
group, matched healthy volunteers received normal aminotransferase
activities, nohistory of liver disease or alcohol abuse and tested negative
for HBV, HCV and HIV infections in this study. All of the patients or their
guardians provided written informed consent, and Medicine's Ethics
Committee of Anhui Medical University approved all aspects of this
study in accordance with the Helsinki Declaration. The liver tissues
were also used for hematoxylin and eosin (H&E) staining and Masson
staining by ﬁxation with 10% formalin.
2.2. Cell culture
An immortalized human HSC line, LX-2 cell line, was donated by Dr.
Lieming Xu from Shuguang Hospital, Shanghai University of Traditional
Chinese Medicine. The LX-2 cells were maintained in Dulbecco's modi-
ﬁed Eagle's medium (DMEM, Gibco, USA) supplemented with 10%
fetal bovine serum (FBS, Gibco, USA) 100 U/ml penicillin, 100 mg/ml
streptomycin, and 2 mM L-glutamine and incubated at 37 °C at an at-
mosphere of 5% CO2. LX-2 cells were plated in a 6-well plate and cul-
tured for 24 h before transfection.2.3. Total RNA isolation and real-time quantitative PCR (RT-qPCR)
Total RNA was isolated from liver tissues and LX-2 cells using TRIzol
reagents (Invitrogen, USA), and the ﬁrst-strand cDNA was synthesized
using Thermoscript RT-PCR synthesis kit (Fermentas, USA) according to
the manufacturer's instructions. Real-time quantitative PCR analyses for
mRNA of α-SMA, Col1A1, DNMT1, TIMP-1, MMP-2, MMP-9 and GAPDH
were performed by using Thermoscript RT-qPCR kits(Fermentas,USA)
in an ABI Prizm step-one plus real-time PCR System (Applied Biosystems,
USA). The mRNA level of GAPDH was used as an internal control. Primer
sequences were listed in Table 1. We used speciﬁc primers for human
MEG3 (forward, 5′-CTGCCCATCTACACCTCACG-3′; and reverse, 5′-CTCT
CCGCCGTCTGCGCTAGGGGCT-3′) from previous publication [23] and for
mouse MEG3 (forward, 5′-GGACTTCACGCACAACACGTT-3′; and reverse,
5′-GTCCCACGCAGGATTCCA-3′) from previous publication [31]. GAPDH
was used as references for MEG3. Each test was done in triple replication
and the 2−ΔΔCt method was used to calculate the expression of mRNA
and MEG3 in tissue samples and cells.2.4. Plasmid construction
pCI-MEG3 was obtained from Addgene bank (Addgene plasmid
44727). The plasmid pCI-MEG3 was ﬁrst constructed by Yunli Zhou
and colleagues [29].We acknowledge the principal investigators. Ectop-
ic expression ofMEG3was achieved byusing thepCI-MEG3 transfection
and empty pCI vector (pCI-control) was used as a control.2.5. Transfection of LX-2 cells
On the day of transfection, the cells were plated in DMEM supple-
mented with 10% FBS at a density of 2–3 × 105 cells/ml and were
transfected with pCI-MEG3 and pCI-control using Lipofectamine 2000
(Invitrogen, USA) according to the manufacturer's instructions. The
culture medium was changed 6 h after transfection, and TGF-β1
(Peprotech, USA) was added at a concentration of 10 ng/ml or
piﬁthrin-μ (Selleckchem, USA) was incubated with concentration of 5
nM and compared to transfected cells without piﬁthrin-μ. Cells were
harvested after 48 h for RT-qPCR, western blot, cell proliferation and
apoptosis analyses.2.6. Treatment of LX-2 cells with 5-azadC
The cells were seeded overnight in culture dishes, 1 μM 5-aza-2′-
deoxycytidine (5-azadC) (Sigma-Aldrich, St. Louis, MO) was added
and was refreshed every 24 h until the 48 h treatment ﬁnished.
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The cells were cultured in serum-free DMEM for 12 h. On the day of
transfection, the cells were plated in DMEM supplemented with 10%
FBS at a density of 2–3 × 105 cells/ml and were transfected with
siRNA-DNMT1 or negative control siRNA (GenaPharma, China) using
Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's
protocol. The culture medium was changed 6 h after transfection, and
TGF-β1 (Peprotech, USA) was added at a concentration of 10 ng/ml.
The sequences of oligonucleotides used are as follows: siRNA-DNMT1:
forward: 5′-GAGGCCUAUAAUGCAAAGATT-3′, reverse: 5′-UCUUUGCA
UUAUAGGCCUC TT-3′, and negative control siRNA: 5′-UUCUCCGAAC
GUGUCACGUTT-3′; 5′-ACGUGACACGUUCGGAGAATT-3′;
2.8. Cell proliferation assays
A Cell Counting Kit-8 (CCK-8) assay was used to measure cell prolif-
eration. The cellswere resuspended in 200 μl of cell culturemediumand
seeded at a density of 5 × 103 cells per well in 96-well culture plates,
incubated overnight to allow for cell attachment, after which they
were transfected with pCI-MEG3, siRNA-DNMT1 or negative control.
The culture medium was changed 6 h after transfection, and TGF-β1
(Peprotech, USA) was added at a concentration of 10 ng/ml. 10 μl of
CCK-8 reagent (obio, Shanghai, China) were added to each well 24, 48,
72 h before the end of incubation. The optical density value (OD) of
each well was measured at a wavelength of 450 nm on ThermomaxH&E
Masson
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Fig. 1. Relative MEG3 expression in CCl4-induced mouse liver ﬁbrosis models, n = 6 mice per
matoxylin and eosin hematoxylin and eosin (H&E) staining andMasson staining (×100). b. The
group are presented (originalmagniﬁcation,×10). c. Theprotein expression ofα-SMA and Col1A
are expressed as relative expression against control expressionwithout treatment. ⁎P b 0.05 vs c
compared with control liver tissues. The results are expressed as relative expression against comicroplate reader (Bio-Tek EL, USA). The result of cell proliferationmea-
surement is expressed as the absorbance at OD450. All experiments
were performed in triplicate and repeated at least three times.
2.9. Cell cycle and apoptosis analysis
For cell cycle analysis, we performed Cell Cycle and Apoptosis Anal-
ysis Kit (Beyotime, China). The cellswerewashed for three times by cold
PBS, and then cells were ﬁxed in 70% ethanol in PBS at−20 °C for 24 h.
After ﬁxation, cells were washed with cold PBS and stained with 0.5 ml
of propidium iodide (PI) staining buffer, which contains 200 mg/ml
RNase A, 50 ug/ml PI, at 37 °C for 30min in the dark. Analyseswere per-
formed on BD FACSVerse (BD Biosciences). The cell debris and ﬁxation
artifacts (aggregates of cells) were gated out and cell populations that
were at the G0/G1, S, and G2/M phases were quantiﬁed by the FlowJo
data analysis software package (TreeStar, USA). The experiments were
repeated for three times.
For apoptosis analysis, quantiﬁcation of apoptotic cells was per-
formed with Annexin-V-FITC Apoptosis Detection Kit (Bestbio, China)
according to the manufacturer's instruction. Cells were discriminated
into viable cells, dead cells, early apoptotic cells, and apoptotic cells.
Analyses were performed on BD FACSVerse (BD Biosciences). Apoptosis
was analyzed with FACS using FlowJo data analysis software package
(TreeStar, USA). The percentage of early apoptotic cells were compared
to control groups from each experiment. All of the samples assayed
were in triplicates.                        6 W                                 8 W
                        6 W                                   8 W
d
group. a. Pathology observation of the experimental mouse liver sections stained with he-
level ofα-SMAwas analyzed by immunohistochemistry. Representative views from each
1was analyzedbywestern blot in control liver tissues and liverﬁbrotic tissues. The results
ontrol. d. Downregulation ofMEG3 expression in CCl4-inducedmouse liver ﬁbrotic tissues
ntrol expression without treatment. ⁎P b 0.05 vs control.
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Fig. 2.RelativeMEG3 expression inhuman liverﬁbrosis tissues, n=5per group. a. Pathologyobservation of the patient liver sections stainedwith hematoxylin and eosin hematoxylin and
eosin (H&E) staining and Masson staining (×100). b. The level of α-SMAwas analyzed by immunohistochemistry. Representative views from each group are presented (original magni-
ﬁcation, ×10). c. The protein expression ofα-SMAand Col1A1was analyzed byWestern blot in livers of patients with liver ﬁbrosis comparedwith healthy livers. The results are expressed
as relative expression against control expression. ⁎P b 0.05 vs control. d. Downregulation of MEG3 expression in livers of patients with liver ﬁbrosis compared with healthy livers. The
results are expressed as relative expression against control expression. ⁎P b 0.05 vs control. e. ISH with anti-Meg3 probe and IHC with α-SMA were performed to determine the
colocalization of MEG3 (green) and α-SMA (red) in CCl4-induced mouse liver ﬁbrosis models. Representative views from control and CCl4-induced mouse liver tissues for 6 weeks are
presented (×100, ×400).
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The methylation status of the MEG3 promoter region was deter-
mined by methylation-speciﬁc PCR (MSP) using bisulﬁte-modiﬁed
DNA. Genomic DNA was extracted using the QIAamp DNA mini kit(Axygen). Two primer sets were used to amplify the promoter region
of the MEG3 that incorporated a number of CpG sites, one speciﬁc for
the methylated sequence (MEG3-M, forward: 5′-TATGAGTTGTAAGC
GGTAG AGTTC-3′; reverse: 5′-TACGAACTTAACGAAAAAAAATCAT-3′)
and the other for the unmethylated sequence (MEG3-U, forward: 5′-
ab
α -SMA
β -actin
0       2      10      30TGF-β1(ng/ml)
α -SMA
β -actin
0h    24 h    48 h    72 hTGF-β1(10ng/ml)
c
d
Fig. 3.Downregulation ofMEG3 in response to TGF-β1. An immortalized humanHSCs, LX-2 cells were treatedwith TGF-β1 (0, 2, 10, and 30 ng/ml) for 48 h inDMEM containing 1% FBS. a.
Dose-dependent effect of TGF-β1 onα-SMAprotein expressionwas analyzed byWestern blot. b. Time-dependent effect of TGF-β1 onα-SMAprotein expressionwas analyzed byWestern
blot. c. Downregulation of MEG3 expression in response to TGF-β1 (0, 2, 10, and 30 ng/ml) for 48 h. d. Downregulation of MEG3 expression in response to TGF-β1 (10 ng/ml) for the
indicated time. The results are expressed as relative expression against control expression without treatment. ⁎P b 0.05 vs control.
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AAAAAAAAATCATACT-3′). The primers used in the present study detect
speciﬁcally the promoter sequence of the MEG3 rather than that of the
MEG3 pseudogene. M and U are the PCR products of methylated and
unmethylated alleles, respectively. The polymerase chain reactions for
MEG3-M and MEG3-U were carried out in a 50 μl volume containing
1× polymerase chain reaction buffer (15 mmol/l MgCl2), 2.5 mmol/l
mixture of dNTPs, 10 pMof each primer, 4 UHotStart TaqDNApolymer-
ase (Qiagen, Frankfurt, Germany), and 25 ng to 50 ng of bisulﬁte-
modiﬁed DNA. Ampliﬁcation was performed in a thermocycler with
the following conditions: 94 °C for 3 min, cycled at 94 °C for 15 s,
60 °C or 57 °C for 15 s, and 72 °C for 15 s (35 cycles), followed by an ex-
tension at 72 °C for 7 min. Methylation-speciﬁc PCR experiments were
performed at least in duplicate.2.11. Western blot analysis
Liver tissues and cells were lysed with RIPA lysis buffer (Beyotime,
China), cytosolic protein was isolated by Cell Mitochondria Isolation
Kit (Beyotime, China) according to the manufacturer's instruction.
Whole extracts were prepared, and protein concentration was detected
using a BCA protein assay kit (Boster, China). Total protein (30 or
50 mg) from samples was separated by SDS-PAGE and blotted onto a
PVDF membrane (Millipore Corp, Billerica, MA, USA). After blocking,
nitrocellulose blots were incubated for 1 h with primary antibodies
diluted in TBS/Tween20 (0.075%) containing 3% Marvel. Mouse poly-
clonal anti-α-SMA (Proteintech, USA) was diluted 1:600, Bax, Bcl-2
and cytochrome c (Boster, China) were diluted 1:200, caspase 3,
cleaved-caspase 3 and caspase 9 (cell Signaling, USA) were diluted
1:600, Mouse monoclonal anti-Col1A1 (Abcam ab90395) was diluted
1:1000, mouse monoclonal antibody directed against DNMT1 (Santa
Cruz, USA) was used at 1:600 as was anti-β-actin (Santa Cruz, USA).
Horseradish peroxidase conjugated anti-mouse and anti-rabbit anti-
bodies were used as secondary antibodies correspondingly. After four
washes in TBS/Tween-20, the membranes were developed with
distilled water for detection of antigen using the enhanced chemilumi-
nescence system. Proteins were visualized with ECL-chemiluminescent
kit (ECL-plus, Thermo Scientiﬁc).2.12. Immunohistochemistry
Liver tissues were ﬁxed in 10% neutral buffered formalin solution,
embedded in parafﬁn, and stained for routine histology. Slides were
dewaxed in xylene and dehydrated in alcohol, and antigen retrieval
was achieved by microwaving in citric saline for 15 min. Thin sections
were deparafﬁnized and treated with 0.3% hydrogen peroxide for
15 min to block endogenous peroxidase activity. The sections were fur-
ther blocked by 2% bovine serum albumin followed by incubation with
primary antibody againstα-SMA (1:200) and DNMT1 (1:50) for 16 h at
4 °C. After rinsing, the sections were incubated with biotinylated sec-
ondary antibody for 60 min at room temperature. α-SMA and DNMT1
expressionwas visualized by 3,3′-diaminobenzidine tetrahydrochloride
(DAB) staining. The sections were counter stained with Mayer's hema-
toxylin for 30 s, dehydrated, and DNMT1 and α-SMA positive areas
within the ﬁbrotic region were then observed.
2.13. Double immunoﬂuorescence staining
Tissues from mice livers were ﬁxed with 4% paraformaldehyde. The
tissues were permeabilized with 0.2% Triton X-100 in 1% bovine serum
albumin (BSA) for 10 min, blocked with 5% BSA for one hour at room
temperature. To determine the colocalization of MEG3 and α-SMA,
FITC-conjugated MEG3 probes (Exiqon) in combination with Cy3-
conjugated anti-α-SMA antibody (1:50 dilution; Boster, China) were
used in the hybridization assays. The cellsweremountedwith SlowFade
Gold antifade reagent with DAPI (Sigma, MO, USA) and images were
taken using ﬂuorescence microscopy. MEG3 was shown as green ﬂuo-
rescence and α-SMA as red ﬂuorescence.
2.14. Statistical analysis
Data are represented as as mean ± SD. The data were analyzed by
One-Way ANOVA (LSD) using the SPSS 15.0 software to determine
their signiﬁcant differences. For changes in mRNA or protein levels,
mRNA (relative expression) and protein (densitometric values) to
respective house-keeping controls were compared. P b 0.05was consid-
ered statistically signiﬁcant.
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3.1. Downregulation of long noncoding RNA MEG3 in murine and human
ﬁbrotic livers
To identify the changes in the MEG3 expression proﬁle between ad-
vanced liver ﬁbrosis and non-ﬁbrotic liver, the degree of liver ﬁbrosis
was ﬁrst determined by hematoxylin eosin (H&E) staining and Masson
staining. Histopathological analysis showed that the degree of liver ﬁ-
brosis progressed in mice that received CCl4 relative to mice receiving
olive oil alone (Fig. 1a). Immunohistochemical and western blot results
demonstrated that themyoﬁbroblastmarkersα-SMAwas stained to in-
vestigate the cellular events inmice and the levels ofα-SMA and Col1A1
were consistently increased in CCl4 mice compared with that in control
mice (Fig. 1b, c). Real-time qPCR result showed thatMEG3was progres-
sively downregulated as liver ﬁbrosis progressed (Fig. 1d).
Next, we correlated these ﬁndings with the data from human
patients and analyzed liver ﬁbrosis samples from patients undergoing
partial liver resection as well as liver samples from non-ﬁbrotic livers.
Histologically, the liver ﬁbrosis tissues exhibited connective tissue ﬁbers
extending from the central vein, early septal formation and collagen de-
position were also established by H&E staining and Masson staining
(Fig. 2a). Similarly, the expression of α-SMA and Col1A1 protein in
livers of patients with liver ﬁbrosis was greater than that with healthy
livers as shown by Immunohistochemical and western blot (Fig. 2b, c).
Interestingly, MEG3 was also downregulated in human liver ﬁbrotica
b
pCI-control
PI
c
d pCI-control
G0/G1: 50.18
S: 41.82%
G2/M: 8%
e
Col1A1
α -SMA
β-acn
Fig. 4. Effect of MEG3 on cell proliferation, cell cycle and apoptosis in TGF-β1-treated LX-2 cells
relative expression against control expression. ⁎P b 0.05. ⁎⁎P b 0.01 vs pCI-control. b. Overexpre
miR-146a in regulating TGF-β1-treated LX-2 cell proliferation was tested by CCK-8 assay. ⁎P b
expressed as relative expression against control expression without treatment. ⁎P b 0.05 vs pCI
strated. d. Effect of MEG3 on cell cycle in TGF-β1-treated LX-2 cells. The results are expressed as
One representative experiment of the three independent experiments is demonstrated. e. The e
levels of α-SMA and Col1A1 were analyzed by western blot. The results are expressed as relatitissues compared with the control liver tissues (Fig. 2d). To determine
if down-regulation of MEG3 in ﬁbrotic micewas due to reduced expres-
sion in HSCs, we used co-labeling MEG3 (ISH with anti-MEG3 probe)
and a-SMA (IHC) to identify whether MEG3 is expressed in HSCs.
Immunoﬂuorescence revealed abundant MEG3 labeling in the liver of
control mice. More inportantly, the double immunoﬂuorescence stain-
ing showed that MEG3 expression was primarily colocalized with that
for α-SMA, suggesting that HSCs may be one of the main sources of
the MEG3 levels present in CCl4-treated livers(Fig. 2e). Thus, it was
concluded that downregulation of MEG3 might have important roles
in liver ﬁbrosis development and progression.
3.2. MEG3 is downregulated in TGF-β1-induced LX-2 cells
Stimulation of HSCs by TGF-β1 is believed to be the key ﬁbrogenic
response in liver ﬁbrosis because the expression of α-SMA can be up-
regulated inHSCs treatedwith TGF-β1 [32]. Here, we showed that treat-
ment of LX-2 cells with TGF-β1 at the concentration of 0, 2, 10 and
30 ng/ml for 48 h could cause the increased expression of α-SMA
protein (Fig. 3a). The expression of α-SMA protein was also increased
in LX-2 cells stimulated with TGF-β1 (10 ng/ml) for 0, 24, 48 and 72 h
(Fig. 3b). These results suggested that α-SMA protein expression
could be increased time- and dose-dependently by TGF-β1. Meanwhile,
MEG3 was downregulated in the time- and dose- dependent manner
when the cells were treated with TGF-β1 at the concentration of 0, 2,
10 and 30 ng/ml for 48 h, or when the cells were treated with TGF-β1pCI-MEG3
AV-FITC
pCI-MEG3
% G0/G1: 62.51%
S: 30.39%
G2/M: 7.1%
TGF-β1(10ng/ml)
. a. Upregulation of MEG3 expression in transfected LX-2 cells. The results are expressed as
ssion ofMEG3 signiﬁcantly inhibited proliferation of TGF-β1-induced LX-2 cells. The role of
0.05 vs pCI-control. c. Effect of MEG3 on apoptosis in TGF-β1-treated HSC. The results are
-control. One representative experiment of the three independent experiments is demon-
relative expression against control expressionwithout treatment. ⁎P b 0.05 vs pCI-control.
xpression of ﬁbrosis-related genesmRNAswas detected by real time qPCR and the protein
ve expression against control expression without treatment. ⁎P b 0.05 vs pCI-control.
2210 Y. He et al. / Biochimica et Biophysica Acta 1842 (2014) 2204–2215(10 ng/ml) for 0, 24, 48 and 72 h (Fig. 3c, d). These results indicated that
TGF-β1 could regulate the expression of MEG3 in LX-2 cells.3.3. Effect of MEG3 on TGF-β1-induced LX-2 cells in vitro
The signiﬁcant decrease of MEG3 expression in liver ﬁbrosis and
activated HSCs prompted us to explore the possible functional role of
MEG3 in stellate cell activation. MEG3 was overexpressed in LX-2 cells
by transfecting them with pCI-MEG3. Real time qPCR analysis of MEG3
levels was performed 48 h posttransfection and revealed that MEG3
expression was signiﬁcantly increased in LX-2 cells compared with re-
spective control (Fig. 4a). Firstly, we investigated the effects of overex-
pression of MEG3 on cell proliferation. The CCK-8 assay found that cell
proliferation was signiﬁcantly suppressed in TGF-β1-induced LX-2 cells
transfected with pCI-MEG3 compared with respective controls (Fig. 4b).
Furthermore, the ﬂow cytometric analyses showed that the proportion
of apoptotic cells induced by transfection of pCI-MEG3 was greater than
that induced by transfection of pCI-control (Fig. 4c). Besides, overexpres-
sion of MEG3 could increase the percentage of the activated HSCs in G0/
G1 phase and decrease the population of cells in S phases (Fig. 4d).
Speciﬁcally, transfection with pCI-MEG3 in TGF-β1-treated LX-2 cells
signiﬁcantly downregulated α-SMA and Col1A1 mRNA and protein
expression and affected the mRNA expression of ﬁbrosis-related genes,
such as tissue inhibitor of metalloproteinase-1 (TIMP-1), matrix metallo-
proteinase 2 (MMP-2), MMP-9 via unknown mechanisms (Fig. 4e).a
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relative expression against control expression without treatment. ⁎P b 0.05 vs control, #P b 0.03.4. Effect of DNA methylation on MEG3 expression
Then, to determinewhether DNAmethylation contributes to the loss
of MEG3 expression, we performed Methylation-Speciﬁc PCR to exam-
ine the role of methylation in deregulation of MEG3 in liver ﬁbrotic
tissues. We found that the promoter regions of MEG3 gene from the
liver tissues of CCl4-treated mice and human liver ﬁbrotic tissues in
which MEG3 expression were downregulated were strongly methylat-
ed, whereas the control liver tissues in which MEG3 expression were
present had unmethylated MEG3 promoter region (Fig. 5a). Important-
ly, treatment of LX-2 cells with TGF-β1 (10 ng/ml) signiﬁcantly induced
hypermethylation of the MEG3 gene (Fig. 5b). These results indicated
aberrant methylation of MEG3 gene promoter, which likely contributed
to the loss ofMEG3 expression in CCl4-treatedmice, human liver ﬁbrotic
tissues and activated LX-2 cells.
To further conﬁrm that the loss of MEG3 expression was caused by
promoter methylation in vitro, we evaluated the effect of the methyla-
tion inhibitor 5-azadC on MEG3 expression. We found that stimulation
with 5-azadC (1 μM) signiﬁcantly abolished TGF-β1-induced aberrant
hypermethylation of the MEG3 and MEG3 expression was robustly
increased in TGF-β1-treated LX-2 cells (Fig. 5b, c). More importantly,
exposure with 5-azadC also diminished TGF-β1-mediated upregulation
of α-SMA and Col1A1 mRNA and protein expression (Fig. 5d, e). In
addition, Cell Counting Kit-8 (CCK-8) assay suggested that treatment
with 5-azadC had an obviously inhibitory effect on TGF-β1-induced
LX-2 cells at different time points (Fig. 5f).         U         M         U
MSP
TGF-β1+5-azadCGF-β1
c
f
ted LX-2 cells. a. Results of MSP analysis of MEG3 gene in CCl4-inducedmouse liver ﬁbrotic
ts of methylated and unmethylated alleles, respectively. b.MSP analysis ofMEG3 promoter
μM) for 48 h.M andU, PCR products of methylated and unmethylated alleles, respectively.
meqPCRanalyses ofMEG3wasperformed. The results are expressed as relative expression
llswere treatedwith orwithout TGF-β1 (10 ng/ml) and 5-azadC (1 μM) for 48h. ThemRNA
. The results are expressed as relative expression against control expression without treat-
fect of 5-azadC (1 μM) on TGF-β1-induced HSC proliferation. The results are expressed as
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2212 Y. He et al. / Biochimica et Biophysica Acta 1842 (2014) 2204–2215To better investigate the methylation-dependent mechanism of
MEG3 alteration,we examined the expression of themain DNAmethyl-
transferases (DNMT) 1 in liverﬁbrotic tissues and TGF-β1-induced LX-2
cells. Immunohistochemical analysis showed that DNMT1 expression
was signiﬁcantly increased in the liver tissues from CCl4-treated mice
and human liver ﬁbrotic tissues compared with the control liver tissues
(Fig. 6a), which was further conﬁrmed by western blot (Fig. 6b). More-
over, treatmentwith TGF-β1 (10 ng/ml)markedly induced upregulated
expression of DNMT1 mRNA and protein in LX-2 cells (Fig. 6c). Next, to
determine whether DNMT1 was involved in the loss of MEG3 expres-
sion in TGF-β1-induced LX-2 cells, the expression of DNMT1 gene was
inhibited by RNA interference. Results of real time PCR and western
blot indicated that cells transfection with DNMT1 siRNA signiﬁcantly
suppressed DNMT1 mRNA and protein expression (Fig. 6d). Further-
more, introduction of DNMT1 siRNA caused a signiﬁcant inhibition of
cell proliferation in TGF-β1-treated LX-2 cells (Fig. 6e). Importantly,
the demethylation of MEG3 gene and an increase in MEG3 expression
were observed in cells incubated with siRNA to DNMT1 (Fig. 6f). More
interestingly, DNMT1 knockdown with siRNA could markedly reduce
α-SMA and Col1A1 mRNA and protein expression in TGF-β1-induced
LX-2 cells compared with control siRNA-tranfected cells (Fig. 6g).
These data indicated that MEG3 expression could be modulated by
alterations in methylation and downregulation of MEG3 observed in
liver ﬁbrotic tissues and TGF-β1-induced LX-2 cells might have been
partly due to hypermethylation of MEG3 gene promoter.3.5. MEG3 increases activation of p53 protein
Recently, accumulating studies reported that re-expression of MEG3
could lead to activation of p53 protein and its downstream targets that
contributed to cell apoptosis and cell growth inhibition [18,20,24,29]. To
further explore the potential mechanisms involved in MEG3-induced
cell apoptosis and growth arrest, we examined the expression of p53
protein after transfection with pCI-MEG3. The results of western blot
analysis showed that the level of p53 protein was markedly increased
in TGF-β1-treated LX-2 cells transfected with pCI-MEG3 compared
with the control (Fig. 7a). Next, wemeasured the signalingmarker pro-
teins, caspase 3 and caspase 9 by Western blot. Interestingly, active
forms of caspase 3 and caspase 9 were signiﬁcantly upregulated in
TGF-β1-treated LX-2 cells tranfected with pCI-MEG3 (Fig. 7b). There is
evidence that p53 participates in the mitochondrial apoptosis pathway
and leads to caspase activation through induction of the release of cyto-
chrome c [33–35]. Therefore, we evaluated the extent of cytochrome c
translocation into cytoplasm in TGF-β1-treated LX-2 cells after transfec-
tion of pCI-MEG3 for 48 h. Herein, a dramatic increase in cytoplasmic
cytochrome c was observed in pCI-MEG3-transfected TGFβ1-treated
LX-2 cells (Fig. 7c). To further conﬁrmwhether MEG3 induced apoptosis
by themitochondrial apoptosis pathway, we investigatedmitochondrial-
dependent apoptosis-related proteins, Bax and Bcl-2. More interestingly,
we found that overexpression ofMEG3 signiﬁcantly induced the Bax/Bcl-
2 ratio in TGF-β1-treated LX-2 cells, which was accompanied by cyto-
chrome c release into the cytoplasm (Fig. 7d). Moreover, piﬁthrin-μ, the
inhibitor of mitochondrial translocation of p53 [36,37], did suppress
MEG3-induced apoptosis associatedwith a cleavage of caspase 3, strong-
ly suggesting that MEG3-induced apoptosis in TGF-β1-induced LX-2
cells was partly mediated by p53-dependent mitochondrial apoptosis
pathway (Fig. 7e, f).Fig. 6. Effects of DNMT1 siRNA onMEG3promotermethylation andMEG3 expression in TGF-β1
to TGF-β1 for 48 h. a. The expression of DNMT1 was analyzed by immunohistochemistry in CC
of DNMT1 was analyzed by Western blot in CCl4-induced mouse liver ﬁbrotic tissues and hum
TGF-β1-treated LX-2 cells. d. ThemRNA and protein expression of DNMT1wasmeasured inDN
the effect of DNMT1 siRNA on TGF-β1-induced HSC proliferation. The results are expressed a
#P b 0.05 vs control siRNA. f.MSP analysis ofMEG3promoter in TGF-β1-treated LX-2 cells with D
respectively. g. The mRNA and protein expression of α-SMA and Col1A1 were analyzed by re
results are expressed as relative expression against control expression without treatment. ⁎P b4. Discussion
Recent improvements in genome-wide surveys have revealed that
only ~1% of the human genome encodes proteins and the majority of
the human genome transcripts are non-coding RNAs, in particular,
long non-coding RNAs (lncRNAs) without evident protein coding func-
tion [38,39]. There are over 3000 huma lncRNAs greater than 200 nt in
length, but less than 1% of them have been manifested in human dis-
eases [40,41]. Although only a minority has been characterized in detail
and they were previously disregarded as transcriptional “noise”, they
are becoming increasingly appreciated in diverse biological processes
for their potential diagnostic, prognostic or therapeutic importance
[10,42].
Liver ﬁbrosis, an excessive wound healing response that occurs in
most forms of chronic liver disease, is characterized by a preponderance
of ﬁbrogenesis (the excess synthesis and deposition of ECM). Activation
of HSCs iswidely accepted to play a critically important role in excessive
deposition of ECM [2,43]. Recently, accumulating evidence demonstrat-
ed that non-condingRNAs,microRNAs (miRNAs) in particular,may play
key roles in regulating HSC functions such as cell proliferation, differen-
tiation, and apoptosis [44]. However, the overall pathophysiological
contributions of lncRNAs to the development of liverﬁbrosis and activa-
tion of HSCs remain blank.
Maternally expressed gene 3 (MEG3, also known as gene trap locus
2 (GTL2)) is reciprocally imprinted with the paternally expressed gene
DLK1 constituting an imprinting domain on human chromosome
14q32 and on mouse chromosome 12 [45]. As a lncRNA, MEG3 does
not encode any proteins and has functions at the RNA level [18,45].
Speciﬁcally, the methylation-dependent dyregulation and function of
MEG3 have been profoundly described in development and progression
of liver cancer. For instance, the expression of theDLK1/MEG3 locuswas
deregulated in human HCC accompanied by extensive aberrations in
DNA methylation leading to aberrant expression of MEG3 RNA [19].
Enforced expression of MEG3 in HCC cells signiﬁcantly decreased both
anchorage-dependent and -independent cell growth, and induced apo-
ptosis [46]. However, whetherMEG3 is involved in the liverﬁbrogenesis
is poorly understood. Therefore, we focused on investigating the role of
MEG3 in the development of liver ﬁbrosis and TGF-β1-induced HSC
activation.
In this study,we found that the expression ofMEG3was consistently
decreased in CCl4-induced mouse progressed liver ﬁbrosis model when
compared to normal tissues. Meanwhile, MEG3 was also found to be
downregulated in human liver ﬁbrotic tissues compared with the
control liver tissues. More importantly, double immunoﬂuorescence
staining conﬁrmed that HSCs may be one of the main sources of the
MEG3 levels present in CCl4-treated livers, suggesting that MEG3 may
play a pivotal role in development of liver ﬁbrosis. TGF-β1 is one of
the critical factors for the activation of HSC during chronic inﬂammation
[47]. We therefore tested whether TGF-β1 might regulate the expres-
sion of MEG3 in HSCs. In line with the downregulation of MEG3 in
liver ﬁbrogenesis, stimulation of human hepatic stellate cell lines LX-2
cells with recombinant TGF-β1 at the concentration of 0, 2, 10 and
30 ng/ml for 48 h or with TGF-β1 (10 ng/ml) for 0, 24, 48 and 72 h
resulted in a signiﬁcant decrease of MEG3 levels, correlatingwith an in-
crease inα-SMAexpression in these cells. These data strongly suggested
that the decreased expression of MEG3 may occur in the development
of liver ﬁbrosis and activation of HSCs. It is well accepted that chronic
hepatitis can develop into liver cirrhosis and HCC, liver ﬁbrosis and-treated LX-2 cells. After DNMT1 siRNAor siControl transfection, the exposure of LX-2 cells
l4-induced mouse liver ﬁbrotic tissues and human liver ﬁbrotic tissues. b. The expression
an liver ﬁbrotic tissues. c. The mRNA and protein expression of DNMT1 was measured in
MT1 siRNA-transfected TGF-β1-treated LX-2 cells. e. The CCK-8was performed to examine
s relative expression against control expression without treatment. ⁎P b 0.05 vs control,
NMT1 siRNA transfection.M andU, PCR products ofmethylated and unmethylated alleles,
al time qPCR and western blot DNMT1 siRNA-transfected TGF-β1-treated LX-2 cells. The
0.05 vs control, #P b 0.05 vs control siRNA.
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needed to better elucidate the critical function and mechanisms of
lncRNA MEG3 in the progression of liver disease.
The methylation of the C5 position of the cytosine base with S-
adenosyl methionine as the methyl donor was reported in approxi-
mately 70–80% of CpG dinucleotides in somatic mammalian cells and
to some extent in non-CpG sequences in embryonic stem cells [48,49].
DNAmethylation is currently the most widely studied epigenetic mod-
iﬁcation and its correlation to pathogenesis of liver ﬁbrosis has been
well established [49,50]. Furthermore, previous studies demonstrated
that DNA methylation contributed to the loss of MEG3 expression in
tumors [26,46,50,51]. Therefore, it is reasonable to hypothesize thatthe decreased expression of MEG3 in liver ﬁbrosis and activation of
HSCs may be due to its promoter hypermethylation. In our study, we
showed that MEG3 promoter hypermethylation was observed in liver
tissues of CCl4-treated mice, human liver ﬁbrotic tissues, and TGF-β1-
treated LX-2 cells by MSP. Importantly, the methylation inhibitor 5-
azadC signiﬁcantly abolished TGF-β1-induced aberrant hypermethyla-
tion of the MEG3 and restored MEG3 expression in TGF-β1-treated
LX-2 cells, which suggested that 5-azadC prevents MEG3 methylation
and subsequently increases MEG3 expression, followed by inhibiting
HSC activation and proliferation. DNA methyltransferase 1 (DNMT1) is
mainly responsible for the maintenance of methylation pattern on the
daughter strand after DNA methylation [52]. In recent study, we found
2214 Y. He et al. / Biochimica et Biophysica Acta 1842 (2014) 2204–2215that the level of DNMT1 expression was analyzed via immunoﬂuores-
cence staining in control liver tissues and liver ﬁbrotic tissues. The result
suggested that more nuclear DNMT1 labeling in livers of rats that had
received CCl4 as compared to control livers [53]. More importantly,
our previous study also revealed that TGF-β1 treatment markedly
induced nuclear translocation of DNMT1 and upregulated expression
of DNMT1 in hepatic stellate cells [54,55]. In particular, it has been pos-
tulated that DNMT1 was upregulated and knockdown of DNMT1 may
lead to loss of promoter hypermethylation resulting in reactivation of
the corresponding genes in activated HSCs [54–56]. Therefore, DNMT1
may play an important role in the development of liver ﬁbrosis and
activation of HSC. In this study, we also found that DNMT1was upregu-
lated in the liver tissues fromCCl4-treatedmice, human liver ﬁbrotic tis-
sues and cultured HSCs after activation. Depletion of DNMT1 by RNAi
suppressed LX-2 cell activation and proliferation, and reversed the
methylation of the MEG3 promoter and subsequently restored MEG3
expression. Intriguingly, treatment with 5-azadC or knockdown of
DNMT1 could downregulate the mRNA and protein level of α-SMA
and Col1A1 in TGF-β1-treated LX-2 cells. Thus, it is possible that overex-
pression of DNMT1 contributes to hypermethylation of the MEG3
promoter with the loss of In order to emphasize the impact of
dyregulated expression and function of MEG3, we investigated the bio-
logical role of MEG3 in TGF-β1-induced LX-2 cells by applying gain-of-
function approach. Results indicated that ectopic expression of MEG3
in TGF-β1-induced LX-2 cells inhibited cell proliferation, led to the
promotion of cell apoptosis, and the decreased expression of ﬁbrosis-
related genes expression.
The known functions of lncRNAswere summarized as signals, decoys,
guides, and scaffolds resulting in modulating activity or localization of
proteins, inducing chromatin remodeling, generating alternative splicing
and so on [9,57]. MEG3 was believed to function to suppress tumor cell
growth, increase protein expression of the tumor suppressor p53, and se-
lectively activate p53 target genes [29,58,59]. In our study, we found that
re-expression of MEG3 could signiﬁcantly activate the level of p53 pro-
tein. As an important tumor suppressor, p53 is capable of modulating
the expression of various target genes leading to activation of down-
stream signal transduction pathways. Furthermore, p53 can intervene
in the intrinsic mitochondria apoptotic pathways involving apoptosome
formation, and culminating in direct caspase activation [60,61]. During
p53-dependent apoptosis, p53 rapidly translocates to the mitochondrial
outer membrane, where it interacts with multi-domain members of the
anti- and proapoptotic Bcl-2 family members to induce mitochondrial
outer membrane permeabilization resulting in cytochrome c release
and caspase activation [33,35,62,63]. Herein, we found that overexpres-
sion of MEG3 could signiﬁcantly induce the Bax/Bcl-2 ratio which was
accompanied by a dramatic increase in cytoplasmic cytochrome c in
TGF-β1-treated LX-2 cells. Moreover, cleaved-caspase-3 and cleaved-
caspase 9 were detected in pCI-MEG3-transfected TGFβ1-treated LX-2
cells. To further conﬁrm whether MEG3 increased TGFβ1-induced LX-2
cells apoptosis by p53-mediated mitochondria apoptotic pathways,
piﬁthrin-μ (the inhibitor of mitochondrial translocation of p53, a small
molecule that reduces binding of p53 to Bcl-2 and Bcl-XL) was used in
pCI-MEG3-transfected TGFβ1-treated LX-2 cells. The results indicated
that piﬁthrin-μ did attenuate MEG3-induced apoptosis associated with
a cleavage of caspase 3, strongly suggesting that p53-dependent mito-
chondrial apoptosis pathway was partly involved in MEG3-induced
apoptosis in TGF-β1-induced LX-2 cells.
On the basis of our ﬁndings, we now propose the following frame-
work that the loss of lncRNA MEG3 expression may be a common
event underlying liver ﬁbrosis, while the methylation-dependent
MEG3may play a critical functional role in liver ﬁbrogenesis and activa-
tion of HSCs, which is evident by the ﬁnding that overexpression of
MEG3 inhibited cell proliferation, increased cell apoptosis, decreased
α-SMA and Col1A1 expression in TGF-β1-treated HSCs, at least in
part, via increasing mitochondrial cytochrome c release subsequently
leading to caspase activation. To our knowledge, this study is the ﬁrstto examine the precise role of MEG3 in liver ﬁbrosis. Our work supports
that MEG3 has potential roles as novel therapeutic target for treating
liver ﬁbrosis. The emerging knowledge in lncRNA advancing ﬁeld will
provide promise for new fundamental knowledge and clinical applica-
tion that will be relevant for liver ﬁbrosis.
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